J&J MedTech growth slows again in Q2 as Abiomed weighs on results

Johnson & Johnson’s MedTech business posted operational sales growth of 3.6% in the second quarter, reaching $8.93 billion, as weaker Abiomed sales weighed on the unit’s performance.